Frank P. Holladay

Fondatore presso TVAX BIOM

72 anni

Consumer Services

Health Technology

Profilo

Frank P.
Holladay is the founder of TVAX Biomedical I LLC and TVAX Biomedical, Inc. He held the title of Chief Medical Officer at both companies, which were founded in 2004 and 2011, respectively.
Holladay received a doctorate degree from Creighton University and an undergraduate degree from the University of California, Berkeley.

Posizioni attive di Frank P. Holladay

Società	Posizione	Inizio
TVAX BIOM	Fondatore	14/07/2011
TVAX Biomedical I LLC TVAX Biomedical I LLC Part of TVAX Biomedical, Inc., TVAX Biomedical I LLC is a clinical stage development company based in Lenexa, KS. TVAX Biomedical I LLC specializes in the development of a novel targeted cell-based immunotherapy for the treatment of cancer. The company's immunotherapeutic cancer treatment platform is based on over 50 years of scientific and medical research into the interactions between cancer and the immune system. TVAX Immunotherapy employs the natural ability of T cells to kill cancer cells and has demonstrated the ability to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy. The key difference between TVAX Biomedical I LLC and other cancer immunotherapy companies is that it uses both cancer vaccine pretreatment to generate cancer-specific T cells and activated "killer" T cell treatment, which has demonstrated significant efficacy. The proprietary treatment has received orphan product designation from the FDA for the prevention and treatment of any primary central nervous system malignancy, providing the company with seven years of marketing exclusivity following FDA marketing approval. The company was founded by Catherine E. Lucasey, Frank P. Holladay, Gray W. Wood. Gray W. Wood has been the CEO of the company since 2004.	Fondatore	01/11/2004

Tutte le posizioni attive di Frank P. Holladay

Formazione di Frank P. Holladay

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Vedi nel dettaglio l'esperienza di Frank P. Holladay

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	4
TVAX Biomedical, Inc. TVAX Biomedical, Inc. BiotechnologyHealth Technology Manufactures and sells healthcare products	Health Technology
Creighton University Creighton University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of California, Berkeley University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
TVAX Biomedical I LLC TVAX Biomedical I LLC Part of TVAX Biomedical, Inc., TVAX Biomedical I LLC is a clinical stage development company based in Lenexa, KS. TVAX Biomedical I LLC specializes in the development of a novel targeted cell-based immunotherapy for the treatment of cancer. The company's immunotherapeutic cancer treatment platform is based on over 50 years of scientific and medical research into the interactions between cancer and the immune system. TVAX Immunotherapy employs the natural ability of T cells to kill cancer cells and has demonstrated the ability to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy. The key difference between TVAX Biomedical I LLC and other cancer immunotherapy companies is that it uses both cancer vaccine pretreatment to generate cancer-specific T cells and activated "killer" T cell treatment, which has demonstrated significant efficacy. The proprietary treatment has received orphan product designation from the FDA for the prevention and treatment of any primary central nervous system malignancy, providing the company with seven years of marketing exclusivity following FDA marketing approval. The company was founded by Catherine E. Lucasey, Frank P. Holladay, Gray W. Wood. Gray W. Wood has been the CEO of the company since 2004.